FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Pipeline reshaping Alongside long-acting protein therapeutics, it is presenting targeted protein degradation candidates at successive conferences. Also seen: Early clinical · first deals

  • Presented preclinical GX-BP1 lung cancer data orally at WCLC 2026. Source

Roles often seen at this stageResearch & development · BD & licensing · Clinical & PV

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

Genexine

A biotech company developing long-acting protein therapeutics and targeted protein degradation (bioPROTAC) candidates.

GX-E4

Approved

A long-acting treatment for anaemia in chronic kidney disease, approved in Indonesia in October 2023 for non-dialysis patients, with a Phase 3 trial in dialysis patients under way in Europe.

GX-BP1

Stage unconfirmed

A bioPROTAC candidate that degrades SOX2, with preclinical lung cancer data presented at AACR 2026 and WCLC 2026.

GX-G6

Phase 3

A diabetes and obesity candidate licensed to a Chinese partner, which has completed Phase 2 and entered Phase 3.

Completion reported

Gave an oral presentation of preclinical GX-BP1 lung cancer data at WCLC 2026.

Official role guide

Genexine careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 제넥신, 글로벌 확장 병행, TPD 파이프라인 ↗머니투데이 · Published 2026-04-16 · Sources checked 2026-11-18 · Original unavailable
  2. 제넥신 GX-BP1, 세계폐암학회서 EGFR 폐암 내성·재발 억제 가능성 공개 ↗한국경제 · Published 2026-09-14 · Sources checked 2026-11-18 · Original unavailable
  3. [AACR] 제넥신, SOX2 표적 '바이오프로탁' 전임상서 폐편평세포암 효능 확인 ↗더바이오 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable